LEADS BIOLABS-B (09887) rose more than 8%. At the time of writing, the stock was up 8.08% to HK$58.05, with a turnover of HK$110 million. On the news front, LEADS BIOLABS announced that, effective March 9, 2026, its shares will be included by Hang Seng Indexes Company as a constituent of the Hang Seng Composite Index and added to the Stock Connect list. The inclusion in the Hang Seng Composite Index and the Stock Connect program represents significant market recognition of the company's performance and value. This move is expected to broaden the company's investor base, enhance trading liquidity of its shares, and further optimize its shareholder structure.

Additionally, on March 6, LEADS BIOLABS announced that the first patient has been successfully enrolled in a Phase II clinical study evaluating its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Weilixin®), in combination therapy as a first-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is reported that LBL-024 (Weilixin®) is a bispecific antibody targeting both PD-L1 and 4-1BB. It is the first globally developed molecule targeting the co-stimulatory receptor 4-1BB to have reached the pivotal single-arm clinical trial stage and has the potential to become the first approved treatment for EP-NEC.